arrow
M

Matthew Mei

city of hope national medical center
H指数:33
被引数:3,966

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin

复发或难治性经典霍奇金淋巴瘤患者一线使用 Brentuximab Vedotin 后的结局

2026-06-250
OAAI
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma

Polatuzumab Vedotin 联合 R-ICE(PolaR-ICE)作为弥漫性大B细胞淋巴瘤的二线治疗方案

2026-03-170
PRE
Association of clonal haematopoiesis and diabetes with outcomes after autologous haematopoietic cell transplantation
2025-12-010
OAAI
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative Analysis

Blinatumomab/Lenalidomide治疗复发/难治性B细胞淋巴瘤的I期研究;毒性、疗效及相关性分析

2025-11-120
OAAI
Outpatient Brexucabtagene Autoleucel in B-Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma

门诊Brexucabtagene autoleucel在B细胞急性淋巴细胞白血病和套细胞淋巴瘤中的应用

2025-08-200
PREAI
Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation

克隆性造血与自体造血干细胞移植后非髓系继发性恶性肿瘤的风险

2025-08-010
OAAI
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial

自体非清髓性造血干细胞移植治疗弥漫性皮肤系统性硬化症:前瞻性、单臂试验中识别毒性及长期结局的疾病危险因素

2025-01-140
OAAI
A Phase 1/2 Study of a ROR1-Targeting CART Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

一项靶向ROR1的CAR-T细胞疗法(ONCT-808)在复发/难治性(R/R)侵袭性B细胞淋巴瘤(BCL)成人患者中的I/II期研究

BLOOD
IF23.1
2024-11-050
PRE
Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

急性淋巴细胞白血病(ALL)和套细胞淋巴瘤(MCL)门诊输注Brexucabtagene Autoleucel(brexu-cel)安全且可行

BLOOD
IF23.1
2024-11-050
PRE
A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

一项Loncastuximab Tesirine联合Mosunetuzumab治疗复发/难治性弥漫大B细胞淋巴瘤的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Nivolumab plus AVD in Advanced-Stage Classic Hodgkin's Lymphoma
2024-10-172
PRE
Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy
2024-10-011
OAAI
Clonal Hematopoiesis is Associated With Severe Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T-Cell (CART) Therapy

克隆性造血与嵌合抗原受体T细胞 (CART) 治疗患者的严重细胞因子释放综合征相关

2024-09-013
PRE
Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)

多中心分析非精原细胞瘤生殖细胞肿瘤(NSGCTs)患者(pts)接受大剂量化疗(HDCT)后的一线(1L)方案(BEP vs VIP)的比较。

2024-09-010
PRE
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
2024-09-012
PRE
Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
2024-05-281
PRE